OCV
Chris Bostick is a Partner at OCV and is passionate about technologies enabling precision medicine. Prior to OCV Dr. Bostick obtained his Ph.D. in Pharmaceutical and Pharmacological Sciences from West Virginia University researching protein immobilization for studying electron transfer and protein-protein interactions in Cytochrome P450s. For his postdoctoral work, he studied precision medicine-based approaches for genetic epilepsies at the Institute for Genomic Medicine at Columbia University. Dr. Bostick holds a B.S. in Biology from Cornell University and a Ph.D. in Pharmacological and Pharmaceutical Sciences from West Virginia University.
Chris serves as a Board Observer for Ossio.
OCV
OCV is a Los Angeles-based venture fund that to date has raised approximately $261M. OCV invests in, owns, and operates companies with differentiated technologies and compelling target markets, with the overriding objective of creating sustainable long-term value. Their core focus sectors include information technology, cloud businesses, e-commerce, media & telecommunications, life sciences & healthcare, and clean technology.